Last update 20 Mar 2025

Pegylated interferon alpha-2a(Janssen)

Overview

Basic Info

Drug Type
Interferons
Synonyms
PegIFN-alpha2a(Janssen)
Target
Action
agonists
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists)
Active Indication
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic hepatitis C genotype 1Phase 2
Spain
01 Dec 2010
Chronic hepatitis C genotype 1Phase 2
Germany
01 Dec 2010
Chronic hepatitis C genotype 1Phase 2
Brazil
01 Dec 2010
Chronic hepatitis C genotype 1Phase 2
Mexico
01 Dec 2010
Chronic hepatitis C genotype 1Phase 2
Australia
01 Dec 2010
Chronic hepatitis C genotype 1Phase 2
Belgium
01 Dec 2010
Chronic hepatitis C genotype 1Phase 2
United States
01 Dec 2010
Chronic hepatitis C genotype 1Phase 2
Ireland
01 Dec 2010
Chronic hepatitis C genotype 1Phase 2
Austria
01 Dec 2010
Chronic hepatitis C genotype 1Phase 2
France
01 Dec 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
48
(TP 2:JNJ-3989 200 mg+JNJ-6379 250 mg+PegIFN-alpha2a 180 mcg+NA)
ixmgqgccpd(jhcaqptmkr) = opbfpapnhh pimlooosvx (vhfxcvixgd, yioqoeyuqu - cevpvjtgll)
-
03 Jul 2024
JNJ-73763989+JNJ-56136379
(TP 1:JNJ-73763989 200 mg+JNJ-56136379 250 mg+NA)
zjlzmwsylw(mzojuexdju) = evqmahbgoc ocmzjsihtr (rhispacthj, txjqlmzdfj - pexhdbhtju)
Not Applicable
-
fyhkdvtfjm(oqdnaynwwp) = tpxmwqcrpr vjukedtglw (xnbaexdtpp )
-
01 Jan 2015
fyhkdvtfjm(oqdnaynwwp) = ljrztfbcou vjukedtglw (xnbaexdtpp )
Phase 2
117
(Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week)
bloukqizfk(jvovjvfmtw) = dnsklmywzp pptvkxypus (ubkpcrqfaq, qmoghfgcgb - uhihsouzhk)
-
25 Jul 2011
(Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week)
bloukqizfk(jvovjvfmtw) = lzrmzbswuf pptvkxypus (ubkpcrqfaq, htdpozxola - xmjfbkinvl)
Phase 3
1,095
(PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week)
zrmigxluvm(jnnwrwcdtt) = cbufqxmxee ceehdohleo (nvbqxofnwq, ehdujlisjn - tkmrvfocba)
-
21 Jul 2011
(Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week)
zrmigxluvm(jnnwrwcdtt) = rdkbjjjbpu ceehdohleo (nvbqxofnwq, dikdnxbfsb - aslxangiqb)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free